Brief: Cns Pharmaceuticals Receives Approval From Switzerland Ethics Committee For Its Potentially Pivotal Study Of Berubicin For The Treatment Of Glioblastoma Multiforme (Gbm)
02/12/2021 13:40
Dec 2 (Reuters) - CNS Pharmaceuticals Inc CNSP.O :
* CNS PHARMACEUTICALS RECEIVES APPROVAL FROM SWITZERLAND
ETHICS
COMMITTEE FOR ITS POTENTIALLY PIVOTAL STUDY OF BERUBICIN FOR THE
TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM)
Source text for Eikon: ID:nPnl8C1Na
Further company coverage: CNSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CNS Pharmaceuticals
See all newsCNS Pharmaceuticals Q2 net loss widens, cash rises after financing
CNS Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM
Brief: Cns Pharmaceuticals Appoints Rami Levin As CEO Effective Jan 1, 2026